Natural Biocon (India) Limited has announced the postponement of its board meeting originally scheduled for April 30, 2026. The company informed BSE Limited through an official communication dated April 30, 2026, that the meeting has been rescheduled to Saturday, May 9, 2026.

Meeting Details and Purpose

The rescheduled board meeting will address several important agenda items as outlined in the company's communication to the stock exchange.

Regulatory Compliance

The meeting postponement follows proper regulatory protocols under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had initially announced the April 30, 2026 board meeting date on April 22, 2026, maintaining transparency with stakeholders throughout the process.

Key Agenda Items

The board will consider and approve several critical documents during the May 9, 2026 meeting:

• Audited financial results for Q4FY26
• Auditor's report for the quarter and year ended March 31, 2026
• Certificate for unmodified opinion from auditors
• Other business matters as deemed necessary

Company Leadership

The official communication was signed by Arunkumar Prajapati, Managing Director of Natural Biocon (India) Limited, bearing DIN: 08281232. The document was digitally signed on April 30, 2026 at 18:10:26 +05'30', ensuring proper authentication and regulatory compliance.

The company has requested BSE Limited to take note of this rescheduling and maintain appropriate records for regulatory purposes.

Natural biocon (India) Limited has formally notified BSE Limited about its upcoming board meeting scheduled for April 30, 2026. The meeting will be held at the company's registered office to deliberate on crucial financial matters for the concluded financial year.

Board Meeting Agenda

The primary agenda for the board meeting includes comprehensive review and approval of key financial documents. The directors will consider and approve the audited financial results for both the quarter and financial year that ended on March 31, 2026.

Regulatory Compliance

The board meeting intimation has been issued in strict compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will also address the auditor's report and certificate for unmodified opinion pursuant to Regulation 33 of the same SEBI regulations.

The agenda includes consideration of related party transactions, ensuring comprehensive disclosure and transparency in accordance with regulatory requirements. An additional provision has been made for any other business items that may arise with the chairman's permission.

Company Leadership

The intimation was digitally signed by Arunkumar Dashrathbhai Prajapati, Managing Director of Natural Biocon (India) Limited, bearing DIN 08281232. The document was signed on April 22, 2026, and formally communicated to the General Manager Corporation Relationship Department at BSE Limited.

The company's registered office is located at A-1007, Sankalp Iconic Tower, opposite Vikram Nagar, Iscon Temple Cross Road, S.G. Highway, Ahmedabad 380054, Gujarat, India. Natural Biocon (India) Limited operates under CIN L24299GJ1992PLC018210 and is listed on BSE with script code 543207.